Fu, Wenyu http://orcid.org/0000-0002-4520-1506
Vasylyev, Dmytro
Bi, Yufei
Zhang, Mingshuang
Sun, Guodong
Khleborodova, Asya
Huang, Guiwu
Zhao, Libo
Zhou, Renpeng
Li, Yonggang
Liu, Shujun
Cai, Xianyi
He, Wenjun
Cui, Min
Zhao, Xiangli
Hettinghouse, Aubryanna
Good, Julia
Kim, Ellen
Strauss, Eric
Leucht, Philipp
Schwarzkopf, Ran
Guo, Edward X.
Samuels, Jonathan
Hu, Wenhuo http://orcid.org/0000-0002-8686-7160
Attur, Mukundan http://orcid.org/0000-0001-7080-8118
Waxman, Stephen G. http://orcid.org/0000-0001-5718-7177
Liu, Chuan-ju http://orcid.org/0000-0002-7181-8032
Article History
Received: 7 November 2022
Accepted: 22 November 2023
First Online: 3 January 2024
Competing interests
: S.G.W. has served as a paid advisor to OliPass, Navega Therapeutics, Sangamo Therapeutics, Chromocell, ThirdRock and Medtronics, and holds stock options in Navega. Compounds and constructs under development by these companies were not used or tested in this study. The remaining authors declare no competing interests.